Skip to main navigation Skip to search Skip to main content

Discovery of a Potent and Highly Isoform-Selective Inhibitor of the Neglected Ribosomal Protein S6 Kinase Beta 2 (S6K2)

  • Stefan Gerstenecker
  • , Lisa Haarer
  • , Martin Schroder
  • , Mark Kudolo
  • , Martin P. Schwalm
  • , Valentin Wydra
  • , Ricardo A. M. Serafim
  • , Apirat Chaikuad
  • , Stefan Knapp
  • , Stefan Laufer
  • , Matthias Gehringer*
  • *Corresponding author for this work

Research output: Indexed journal article › Article › peer-review

23 Citations (Web of Science)

Abstract

Simple Summary:& nbsp;The two human p70 ribosomal S6 kinases, S6K1 and S6K2, have been associated with a variety of cellular processes and human pathologies, especially cancer. Thus far, only S6K1 was thoroughly studied and selectively addressed by small molecule inhibitors. Despite growing evidence suggesting S6K2 as a promising anticancer target, this isoform has been severely neglected, which can partly be attributed to the lack of isoform-selective inhibitors to study its function. By exploiting a cysteine residue exclusive to S6K2, we were able to generate the first known isoform-selective S6K2 inhibitor. Besides its excellent selectivity against S6K1 and other human kinases, the compound showed weak intrinsic reactivity and promising in vitro metabolic stability. Our proof-of-concept study provides a basis for the development of high quality S6K2 chemical probes to validate this kinase as a target for therapeutic interventions.</p><br></p>The ribosomal protein S6 kinase beta 2 (S6K2) is thought to play an important role in malignant cell proliferation, but is understudied compared to its closely related homolog S6 kinase beta 1 (S6K1). To better understand the biological function of S6K2, chemical probes are needed, but the high similarity between S6K2 and S6K1 makes it challenging to selectively address S6K2 with small molecules. We were able to design the first potent and highly isoform-specific S6K2 inhibitor from a known S6K1-selective inhibitor, which was merged with a covalent inhibitor engaging a cysteine located in the hinge region in the fibroblast growth factor receptor kinase (FGFR) 4 via a nucleophilic aromatic substitution (SNAr) reaction. The title compound shows a high selectivity over kinases with an equivalently positioned cysteine, as well as in a larger kinase panel. A good stability towards glutathione and Na-acetyl lysine indicates a non-promiscuous reactivity pattern. Thus, the title compound represents an important step towards a high-quality chemical probe to study S6K2-specific signaling.</p>
Original languageEnglish
Article number5133
Number of pages11
JournalCancers
Volume13
Issue number20
DOIs
Publication statusPublished - 2 Oct 2021
Externally publishedYes

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

  1. SDG 3 - Good Health and Well-being
    SDG 3 Good Health and Well-being

Keywords

  • Rps6kb2
  • S6k2
  • Chemical probes
  • Covalent inhibitors
  • p70S6K2
  • p70S6Kb
  • Protein kinases

Fingerprint

Dive into the research topics of 'Discovery of a Potent and Highly Isoform-Selective Inhibitor of the Neglected Ribosomal Protein S6 Kinase Beta 2 (S6K2)'. Together they form a unique fingerprint.

Cite this